vs
豪洛捷（HOLX）与Sunrun Inc.（RUN）财务数据对比。点击上方公司名可切换其他公司
Sunrun Inc.的季度营收约是豪洛捷的1.1倍（$1.2B vs $1.0B），豪洛捷净利率更高（17.1% vs 8.9%，领先8.2%），Sunrun Inc.同比增速更快（123.5% vs 2.5%），过去两年Sunrun Inc.的营收复合增速更高（59.0% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Sunrun Inc.是美国知名的光伏系统及电池储能产品供应商，业务以服务住宅客户为主，2007年成立，总部位于加利福尼亚州旧金山，致力于为家庭用户提供高效的清洁能源解决方案。
HOLX vs RUN — 直观对比
营收规模更大
RUN
是对方的1.1倍
$1.0B
营收增速更快
RUN
高出121.0%
2.5%
净利率更高
HOLX
高出8.2%
8.9%
两年增速更快
RUN
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.2B |
| 净利润 | $179.1M | $103.6M |
| 毛利率 | 56.0% | — |
| 营业利润率 | 22.6% | 8.4% |
| 净利率 | 17.1% | 8.9% |
| 营收同比 | 2.5% | 123.5% |
| 净利润同比 | -10.9% | 103.7% |
| 每股收益（稀释后） | $0.79 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRUN
| Q4 25 | $1.0B | $1.2B | ||
| Q3 25 | $1.0B | $724.6M | ||
| Q2 25 | $1.0B | $569.3M | ||
| Q1 25 | $1.0B | $504.3M | ||
| Q4 24 | $1.0B | $518.5M | ||
| Q3 24 | $988.0M | $537.2M | ||
| Q2 24 | $1.0B | $523.9M | ||
| Q1 24 | $1.0B | $458.2M |
净利润HOLXRUN
| Q4 25 | $179.1M | $103.6M | ||
| Q3 25 | $187.2M | $16.6M | ||
| Q2 25 | $194.9M | $279.8M | ||
| Q1 25 | $-17.4M | $50.0M | ||
| Q4 24 | $201.0M | $-2.8B | ||
| Q3 24 | $178.6M | $-83.8M | ||
| Q2 24 | $194.5M | $139.1M | ||
| Q1 24 | $169.9M | $-87.8M |
毛利率HOLXRUN
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
营业利润率HOLXRUN
| Q4 25 | 22.6% | 8.4% | ||
| Q3 25 | 22.6% | 0.5% | ||
| Q2 25 | 24.9% | -19.7% | ||
| Q1 25 | -0.7% | -22.8% | ||
| Q4 24 | 22.5% | -628.0% | ||
| Q3 24 | 23.3% | -23.8% | ||
| Q2 24 | 24.1% | -24.4% | ||
| Q1 24 | 20.7% | -40.0% |
净利率HOLXRUN
| Q4 25 | 17.1% | 8.9% | ||
| Q3 25 | 17.8% | 2.3% | ||
| Q2 25 | 19.0% | 49.1% | ||
| Q1 25 | -1.7% | 9.9% | ||
| Q4 24 | 19.7% | -542.7% | ||
| Q3 24 | 18.1% | -15.6% | ||
| Q2 24 | 19.2% | 26.5% | ||
| Q1 24 | 16.7% | -19.2% |
每股收益（稀释后）HOLXRUN
| Q4 25 | $0.79 | $0.38 | ||
| Q3 25 | $0.84 | $0.06 | ||
| Q2 25 | $0.86 | $1.07 | ||
| Q1 25 | $-0.08 | $0.20 | ||
| Q4 24 | $0.87 | $-12.59 | ||
| Q3 24 | $0.75 | $-0.37 | ||
| Q2 24 | $0.82 | $0.55 | ||
| Q1 24 | $0.72 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | — |
| 总债务越低越好 | $2.5B | $14.7B |
| 股东权益账面价值 | $5.2B | $3.1B |
| 总资产 | $9.2B | $22.6B |
| 负债/权益比越低杠杆越低 | 0.48× | 4.69× |
8季度趋势，按日历期对齐
现金及短期投资HOLXRUN
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.2B | — |
总债务HOLXRUN
| Q4 25 | $2.5B | $14.7B | ||
| Q3 25 | $2.5B | $14.6B | ||
| Q2 25 | $2.5B | $14.0B | ||
| Q1 25 | $2.5B | $13.6B | ||
| Q4 24 | $2.5B | $12.9B | ||
| Q3 24 | $2.5B | $12.5B | ||
| Q2 24 | $2.5B | $12.0B | ||
| Q1 24 | $2.6B | $11.1B |
股东权益HOLXRUN
| Q4 25 | $5.2B | $3.1B | ||
| Q3 25 | $5.0B | $3.0B | ||
| Q2 25 | $4.8B | $2.9B | ||
| Q1 25 | $4.6B | $2.6B | ||
| Q4 24 | $4.8B | $2.6B | ||
| Q3 24 | $5.1B | $5.3B | ||
| Q2 24 | $5.0B | $5.4B | ||
| Q1 24 | $4.8B | $5.2B |
总资产HOLXRUN
| Q4 25 | $9.2B | $22.6B | ||
| Q3 25 | $9.0B | $22.2B | ||
| Q2 25 | $8.8B | $21.2B | ||
| Q1 25 | $8.5B | $20.4B | ||
| Q4 24 | $8.7B | $19.9B | ||
| Q3 24 | $9.2B | $22.1B | ||
| Q2 24 | $8.9B | $21.4B | ||
| Q1 24 | $8.7B | $20.8B |
负债/权益比HOLXRUN
| Q4 25 | 0.48× | 4.69× | ||
| Q3 25 | 0.50× | 4.90× | ||
| Q2 25 | 0.52× | 4.80× | ||
| Q1 25 | 0.55× | 5.19× | ||
| Q4 24 | 0.53× | 5.05× | ||
| Q3 24 | 0.49× | 2.36× | ||
| Q2 24 | 0.51× | 2.23× | ||
| Q1 24 | 0.53× | 2.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $96.9M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.4% | — |
| 现金转化率经营现金流/净利润 | 1.28× | 0.94× |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流HOLXRUN
| Q4 25 | $229.9M | $96.9M | ||
| Q3 25 | $355.1M | $-121.5M | ||
| Q2 25 | $343.3M | $-292.7M | ||
| Q1 25 | $169.4M | $-104.2M | ||
| Q4 24 | $189.3M | $-258.4M | ||
| Q3 24 | $367.0M | $-156.2M | ||
| Q2 24 | $405.8M | $-208.5M | ||
| Q1 24 | $292.4M | $-143.1M |
自由现金流HOLXRUN
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | $-156.4M | ||
| Q2 24 | $385.3M | — | ||
| Q1 24 | $279.6M | — |
自由现金流率HOLXRUN
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | -29.1% | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 27.5% | — |
资本支出强度HOLXRUN
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | 0.0% | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.3% | — |
现金转化率HOLXRUN
| Q4 25 | 1.28× | 0.94× | ||
| Q3 25 | 1.90× | -7.33× | ||
| Q2 25 | 1.76× | -1.05× | ||
| Q1 25 | — | -2.08× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | -1.50× | ||
| Q1 24 | 1.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RUN
| Products | $692.3M | 60% |
| Customer Agreements | $435.2M | 38% |
| Manufactured Product Other | $56.7M | 5% |
| Incentives | $31.3M | 3% |
